XML 50 R16.htm IDEA: XBRL DOCUMENT

10. SEGMENTS

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

10. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immune globulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1). The Plasma Collection Centers segment consists of one FDA-licensed source plasma collection facility for the nine months ended September 30, 2019 and two FDA-licensed facilities for the nine months ended September 30, 2018. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended September 30, 2019
		ADMA BioManufacturing				Plasma Collection Centers				Corporate				Consolidated

Revenues		$	5,869,082			$	1,317,713			$	35,708			$	7,222,503

Cost of product revenue			6,585,143				1,331,077				—				7,916,220

Loss from operations			(6,007,646	)			(470,263	)			(2,572,519	)			(9,050,428	)

Interest and other expense, net			(255,384	)			—				(2,132,647	)			(2,388,031	)

Net loss			(6,263,030	)			(470,263	)			(4,705,166	)			(11,438,459	)

Depreciation and amortization			700,981				113,957				3,190				818,128

Total assets			87,400,781				4,105,208				46,273,784				137,779,773

Three Months Ended September 30, 2018
		ADMA BioManufacturing				Plasma Collection Centers				Corporate				Consolidated

Revenues		$	1,985,630			$	2,208,972			$	35,708			$	4,230,310

Cost of product revenue			7,671,279				1,492,830				—				9,164,109

Loss from operations			(10,214,933	)			(1,257,196	)			(2,319,271	)			(13,791,400	)

Interest and other expense, net			(255,410	)			849				(1,089,524	)			(1,344,085	)

Net loss			(10,470,343	)			(1,256,347	)			(3,408,795	)			(15,135,485	)

Total assets			56,123,178				5,524,105				44,697,817				106,345,100

Depreciation and amortization expense			651,317				191,547				4,193				847,057

Nine Months Ended September 30, 2019
		ADMA BioManufacturing				Plasma Collection Centers				Corporate				Consolidated

Revenues		$	11,215,510			$	5,989,399			$	107,125			$	17,312,034

Cost of product revenue			22,695,870				5,116,765				—				27,812,635

Loss from operations			(25,300,237	)			(832,864	)			(7,464,417	)			(33,597,518	)

Interest and other (expense) income, net			(671,600	)			13,560				(5,027,654	)			(5,685,694	)

Gain on transfer of plasma center assets			—				11,527,421				—				11,527,421

Loss on extinguishment of debt			—				—				(9,962,495	)			(9,962,495	)

Net (loss) income			(25,971,837	)			10,708,117				(22,454,566	)			(37,718,286	)

Depreciation and amortization			2,077,221				342,156				10,173				2,429,550

Capital expenditures			2,185,554				31,988				—				2,217,542

Nine Months Ended September 30, 2018
		ADMA BioManufacturing				Plasma Collection Centers				Corporate				Consolidated

Revenues		$	5,796,597			$	7,025,144			$	107,125			$	12,928,866

Cost of product revenue			26,334,602				4,717,917				—				31,052,519

Loss from operations			(32,656,560	)			(3,238,013	)			(7,846,711	)			(43,741,284	)

Interest and other expense, net			(732,623	)			(22	)			(3,231,529	)			(3,964,174	)

Net loss			(33,389,183	)			(3,238,035	)			(11,078,240	)			(47,705,458	)

Depreciation and amortization			1,922,448				581,059				18,989				2,522,496

Capital expenditures			772,339				504,255				—				1,276,594